Company
SeaStar Medical
Nasdaq: ICU
Denver, Colorado commercial-stage healthcare company. Develops the Selective Cytopheretic Device (SCD), an extracorporeal cell-directed immunomodulation therapy; its QUELIMMUNE product is FDA-approved for pediatric acute kidney injury due to sepsis.
1 story
Regulatory News has published 1 story about SeaStar Medical on 7 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 7 October 2026.
This page is generated from Regulatory News’ editorial coverage of SeaStar Medical. It is not an advertisement.
On the record
- Company
- SeaStar Medical Holding Corporation (Nasdaq: ICU)
- Headquarters
- Denver, Colorado
- Regulator
- U.S. Food and Drug Administration (CDRH)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
